Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by SAB Biotherapeutics, Inc.

< Previous 1 2 Next >
SAB Biotherapeutics Announces Private Placement of up to $130 Million to Advance Development of Lead Drug Candidate for Type 1 Diabetes
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
Tickers SABS SABSW
SAB Biotherapeutics Provides Company Update for Q2 2023 Financial Results
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
Tickers SABS SABSW
SAB Biotherapeutics Presents Positive IND-Enabling GLP Toxicology Study for SAB-142, a Novel Immunotherapeutic for Type 1 Diabetes at FOCIS 2023
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
Tickers SABS SABSW
SAB Biotherapeutics to Present Novel Human IgG Platform with Positive Data and Breakthrough Therapy and Fast-Track Designations for Influenza Treatment at BIO 2023 International Convention
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
Tickers SABS SABSW
SAB Biotherapeutics Presents Virtual 2023 R&D Day Portfolio Update: Breakthrough Immunotherapy Innovations
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
Tickers SABS SABSW
SAB Biotherapeutics Provides Company Update for Q1 2023 Financial Results
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
Tickers SABS SABSW
SAB Biotherapeutics Announces First Publication of Promising Nonclinical Data for SAB-183 Against Pneumonic Plague in the Journal Antibodies
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
Tickers SABS SABSW
SAB Biotherapeutics Announces Progress on U.S. FDA’s Phased Review of Company’s Groundbreaking DiversitAb™ Platform
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
Tickers SABS SABSW
SAB Biotherapeutics Presents Positive Phase 1 and 2a Data for SAB-176 Influenza Immunotherapy at ISIRV-AVG Conference
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
Tickers SABS SABSW
SAB Biotherapeutics to Present at Sidoti Virtual Investor Conference, May 10-11
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
Tickers SABS SABSW
SAB Biotherapeutics Announces Positive Results from Phase 3 Trial of SAB-185 in Patients with COVID-19 at High-Risk for Severe Complications
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
Tickers SABS SABSW
SAB Biotherapeutics Announces U.S. FDA Grants Breakthrough Therapy Designation to SAB-176 Influenza Immunotherapy
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
Tickers SABS SABSW
SAB Biotherapeutics Granted Fast Track Designation from FDA for SAB-176 Influenza Immunotherapy with High Cross-Reactivity to Multiple Strains of Influenza
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
Tickers SABS SABSW
SAB Biotherapeutics Announces Appointment of Erick Lucera, CFA to Board of Directors
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
Tickers SABS SABSW
SAB Biotherapeutics Provides Company Update for Full Year 2022
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
Tickers SABS SABSW
SAB Biotherapeutics CEO Eddie Sullivan, PhD, to Present Next Generation Biologics in Immunology at BIO CEO & Investor Conference
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
Tickers SABS SABSW
SAB Biotherapeutics Receives an Additional $8.2 Million in Closeout of DoD Contract
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
Tickers SABS SABSW
SAB Biotherapeutics Successfully Concludes IND-Enabling GLP Toxicology Study for SAB-142, a Novel Immunotherapeutic for Type 1 Diabetes
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
Tickers SABS SABSW
SAB Biotherapeutics’ CMO Alexandra Kropotova to Deliver Presentation on Next Generation Biologics in Immunology at Biotech Showcase
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
Tickers SABS SABSW
SAB Biotherapeutics Novel DiversitAb™ Platform Proven to Develop Anti-idiotype Antibodies to Help Treat Autoimmune Diseases
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
Tickers ASX:CSL SABS SABSW
SAB Biotherapeutics CMO Selected to Present at the January 2023 Biotech Showcase in San Francisco
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
Tickers SABS SABSW
SAB Biotherapeutics Announces $7.9 Million Private Placement of Common Stock
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
Tickers SABS SABSW
SAB Biotherapeutics Initiates IND-Enabling GLP Toxicology Study for SAB-142, Novel Immunotherapeutic for Type 1 Diabetes
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
Tickers SABS SABSW
SAB Biotherapeutics Provides Company Update for Q3 2022 Financial Results
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
Tickers SABS SABSW
SAB Biotherapeutics Presents ‘Novel Biologic Therapeutics for Infectious Diseases’ at U.S. Pharma Partnering Summit 2022
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
Tickers SABS SABSW
SAB Biotherapeutics Presents Overview of DiversitAb™ Platform and Data Showing Benefits of Fully-Human Polyclonal Antibodies Derived from Cows vs. Human-Derived Plasma, at 2022 Plasma Product Biotechnology Conference
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
Tickers SABS SABSW
SAB Biotherapeutics Announces Exclusive Manufacturing Partnership with Emergent BioSolutions
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
Tickers EBS SABS SABSW
SAB Biotherapeutics Unveils New Data at ISIRV OPTIONS XI Conference Validating SAB-176 Proof of Concept in Reducing Viral Load and Improving Symptoms of Influenza and Showing SAB-185 Effective Against Multiple COVID-19 Variants Including Omicron
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
Tickers SABS SABSW
SAB Biotherapeutics to Host Virtual R&D Day on October 13, 2021
From SAB Biotherapeutics, Inc.
Via Business Wire
SAB Biotherapeutics Announces First Patient Dosed in Phase 3 NIH ACTIV-2 Trial Evaluating SAB-185 for Treatment of COVID-19
From SAB Biotherapeutics, Inc.
Via Business Wire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.